Immunotherapy: are we making a difference?
There is a 10-20 year history of immunotherapeutic approaches in metastatic renal cell cancer, which have produced a consistent demonstration of anti-tumour effect in a small percentage of patients. Clarification of dose and schedule of current agents continues to be modified. New technologies for immune system activation are attempting to enhance the response rate and improve outcome. Anti-proliferative effects of immunotherapy produce prolongation of stable disease, and new agents are being developed to enhance this approach.
Dutcher
J P
JP
New York Medical College and Our Lady of Mercy Cancer Centre, Bronx 10466, USA. jpd4401@aol.com
D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000639:trends*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome